Novo Nordisk’s Worst Month Since 2002 Highlights Growth Concerns
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Health Care Roundup: Market Talk
Find insight on Novo Nordisk, product-specific tariffs, Pro Medicus and more in the latest Market Talks on Health Care.
Financial World5d
Vietnam reduces tariffs on US imports to balance trade deficit
Vietnam will, among other things, reduce tariffs on liquefied natural gas from the US from the previous higher rates to just 2 percent.
Vietnam clears the way for Musk's Starlink in five-year satellite internet trial
SpaceX reportedly proposed investing $1.5 billion in Vietnam tied to its Starlink rollout, with the company also exploring ...
Step Aside, Novo Nordisk. This Is Europe’s No. 1 Company Now.
The two stocks have been trending in different directions for months. Here's what that says about the broader market.
NBC Los Angeles6d
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
ScandAsia6d
Two Nordic representatives on the board of Eurocham Vietnam
EuroCham Vietnam announced yesterday, 24 March 2025, its new 17-member executive board for the 2025 term. The Board included ...